Stock RPTX REPARE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Repare Therapeutics Inc.

Equities

RPTX

US7602731025

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
3.48 USD +3.88% Intraday chart for Repare Therapeutics Inc. +11.54% -52.33%
May. 08 Top Premarket Gainers MT
May. 08 Repare Therapeutics Shares Rise Premarket Wednesday After Company Swings to Q1 Net Income Amid Higher Revenue MT

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company appears to be poorly valued given its net asset value.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
REPARE THERAPEUTICS INC. Stock Repare Therapeutics Inc.
-52.33% 148M -
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.64B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
A
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
C
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
B+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. RPTX Stock
  4. Ratings Repare Therapeutics Inc.